Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Beijing Inno Medicine Co. Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is localized in 1 distinct art unit, indicating a specific focus for the current patent application. The matter is being reviewed by 1 distinct examiner, which means the patent office engagement is limited to a single point of contact for this entity.
The busiest examiner for this portfolio is JONES, DAMERON LEVEST, who is handling 1 pending office action. Since there is 1 distinct examiner and 1 distinct art unit, the success of the prosecution will depend on the specific feedback and examination style of this individual. This focused approach in the Biotechnology & Pharmaceuticals sector indicates that the current intellectual property efforts are centered on a specific innovation. The involvement of the examiner simplifies the prosecution strategy but places significant importance on the interactions with JONES, DAMERON LEVEST.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 2 | 63.1% | +9.5% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689166 | ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR | JONES, DAMERON LEVEST | 16d overdue |
| 19388923 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689166 | ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR | JONES, DAMERON LEVEST | 16d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19388923 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | 1618 | §103§112Other | Non-Final OA | — | Pending | Nov 13, 2025 |
| 18689166 | ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR | JONES, DAMERON LEVEST | 1618 | §103§112Other | Non-Final OA | 16d overdue | Pending | Mar 05, 2024 |
| 18530122 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | 1618 | §103 | Non-Final OA | 72d overdue | Pending | Dec 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial